Wyeth

Medimmune Limited

Cambridge Antibody Technology Limited

Caroline S Russell

Viia Valge-Archer

Geertruida Machteld Veldman

Neil M Wolfman

Ralph Raymond Minter

Jing Li

Davinder Gill

Lynette A Fouser

David C Lowe

Monique V Davies

Kristie Grove Bridges

Suzanne E Cohen

Albert George Thom

Anne Field

Kening Song

Clive R Wood

Mary Collins

Beatriz M Carreno

Deborah P Luxenberg

Laura L Carter

John Edward Andrews

Jason Jussif

Frances K Bennett

Matthew Alexander Sleeman

Fraser Welsh

Duncan James Cochrane

Maurice Needham

Vila Valge-Archer

Caroline Langham

Patrick Dufner

Viia Valge-archer

Davinder S Gill

Albert B Thom

The disclosure provides novel antibodies against growth and differentiation factor-8 (GDF-8), in particular human antibodies, and antibody fragments, including those that inhibit GDF-8 activity in vitro and/or in vivo. The disclosure also provides methods for diagnosing, preventing, or treating degenerative disorders of muscle or bone, or disorders of insulin metabolism.

Neutralizing antibodies against GDF-8 and uses therefor

Binding members, especially antibody molecules, for interleukin 17 (IL-17). The binding members are useful for the treatment of disorders associated with interleukin 17 such as rheumatoid arthritis.

Antibodies to IL-17A and uses thereof

The present application provides human antibodies and antigen binding fragments thereof that specifically bind to the human interleukin-22 (IL-22). The antibodies can act as antagonists of IL-22 activity, thereby modulating immune responses in general, and those mediated by IL-22 in particular. The disclosed compositions and methods may be used for example, in diagnosing, treating or preventing inflammatory disorders, autoimmune diseases, allergies, septic shock, infectious disorders, transplant rejection, cancer, and other immune system disorders.

Nucleic acid encoding antibody to human IL-22

Antibodies to human IL-22

This disclosure provides antibodies and antigen-binding fragments that can act as agonists and/or antagonists of PD-1 (Programmed Death 1), thereby modulating immune responses in general, and those mediated by TcR and CD28, in particular. The disclosed compositions and methods may be used for example, in treating autoimmune diseases, inflammatory disorders, allergies, transplant rejection, cancer, and other immune system disorders.

Nucleic acids encoding antibodies against PD-1

Antibodies against human IL-22 and uses therefor

Methods of upmodulating adaptive immune response using anti-PD-1 antibodies

Antibodies against PD-1

Growing community of inventors

Hertfordshire, United Kingdom

Caroline S Russell